Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses

2013 ◽  
Vol 165 (1) ◽  
pp. 16-21 ◽  
Author(s):  
S.B. Rizwan ◽  
W.T. McBurney ◽  
K. Young ◽  
T. Hanley ◽  
B.J. Boyd ◽  
...  
Keyword(s):  
Immune Responses ◽  
Lipid A ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid

scholarly journals Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines

Viruses ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1118 ◽  
Author(s):  
Chen Chen ◽  
Chengguang Zhang ◽  
Ruiming Li ◽  
Zongmei Wang ◽  
Yueming Yuan ◽  
...  
Keyword(s):  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Lipid A ◽  
Survival Ratio ◽  
Effective Measure ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid

Rabies, as one of the most threatening zoonoses in the world, causes a fatal central nervous system (CNS) disease. So far, vaccination with rabies vaccines has been the most effective measure to prevent and control this disease. At present, inactivated rabies vaccines are widely used in humans and domestic animals. However, humoral immune responses induced by inactivated rabies vaccines are relatively low and multiple shots are required to achieve protective immunity. Supplementation with an adjuvant is a practical way to improve the immunogenicity of inactivated rabies vaccines. In this study, we found that monophosphoryl-lipid A (MPLA), a well-known TLR4 agonist, could significantly promote the maturation of bone marrow-derived dendritic cells (BMDC) through a TLR4-dependent pathway in vitro and the maturation of conventional DCs (cDCs) in vivo. We also found that MPLA, serving as an adjuvant for inactivated rabies vaccines, could significantly facilitate the generation of T follicular helper (Tfh) cells, germinal center (GC) B cells, and plasma cells (PCs), consequently enhancing the production of RABV-specific total-IgG, IgG2a, IgG2b, and the virus-neutralizing antibodies (VNAs). Furthermore, MPLA could increase the survival ratio of mice challenged with virulent RABV. In conclusion, our results demonstrate that MPLA serving as an adjuvant enhances the intensity of humoral immune responses by activating the cDC–Tfh–GC B axis. Our findings will contribute to the improvement of the efficiency of traditional rabies vaccines.

scholarly journals ESAT-6 Subunit Vaccination againstMycobacterium tuberculosis

2000 ◽  
Vol 68 (2) ◽  
pp. 791-795 ◽  
Author(s):  
Lise Brandt ◽  
Martin Elhay ◽  
Ida Rosenkrands ◽  
Erik B. Lindblad ◽  
Peter Andersen
Keyword(s):  
Immune Responses ◽  
Lipid A ◽  
T Cell Response ◽  
Cell Mediated Immunity ◽  
Adjuvant Activity ◽  
Humoral Immune ◽  
Cellular Immune Responses ◽  
Humoral Immune Responses ◽  
Monophosphoryl Lipid A ◽  
Cellular Immune

ABSTRACT The ESAT-6 antigen from Mycobacterium tuberculosis is a dominant target for cell-mediated immunity in the early phase of tuberculosis (TB) in TB patients as well as in various animal models. The purpose of our study was to evaluate the potential of ESAT-6 in an experimental TB vaccine. We started out using dimethyl dioctadecylammonium bromide (DDA), an adjuvant which has been demonstrated to be efficient for the induction of cellular immune responses and has been used successfully before as a delivery system for TB vaccines. Here we demonstrate that, whereas immune responses to both short-term-culture filtrate and Ag85B are efficiently induced with DDA, this adjuvant was inefficient for the induction of immune responses to ESAT-6. Therefore, we investigated the modulatory effect of monophosphoryl lipid A (MPL), an immunomodulator which in different combinations has demonstrated strong adjuvant activity for both cellular and humoral immune responses. We show in the present study that vaccination with ESAT-6 delivered in a combination of MPL and DDA elicited a strong ESAT-6-specific T-cell response and protective immunity comparable to that achieved withMycobacterium bovis BCG.

Monophosphoryl lipid A: an effective adjuvant for potentiating mucosal immune responses

1999 ◽  
Vol 5 (3) ◽  
pp. 181-182 ◽  
Author(s):  
Suzanne M. Michalek ◽  
Noel K. Childers ◽  
Terry Greenway ◽  
George Hajishengallis ◽  
J. Terry Ulrich
Keyword(s):  
Immune Responses ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Mucosal Immune Responses

scholarly journals A Potent Adjuvant Monophosphoryl Lipid A Triggers Various Immune Responses, but Not Secretion of IL-1β or Activation of Caspase-1

2006 ◽  
Vol 176 (2) ◽  
pp. 1203-1208 ◽  
Author(s):  
Kazuo Okemoto ◽  
Kiyoshi Kawasaki ◽  
Kentaro Hanada ◽  
Masami Miura ◽  
Masahiro Nishijima
Keyword(s):  
Immune Responses ◽  
Lipid A ◽  
Caspase 1 ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid

scholarly journals STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity

2018 ◽  
Vol 30 (8) ◽  
pp. 385-385
Author(s):  
Sanjay Varikuti ◽  
Steve Oghumu ◽  
Gayathri Natarajan ◽  
Jennifer Kimble ◽  
Rachel H Sperling ◽  
...  
Keyword(s):  
Immune Responses ◽  
Lipid A ◽  
Adjuvant Activity ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Th1 And Th2

scholarly journals Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice

Blood ◽  
2012 ◽  
Vol 119 (9) ◽  
pp. 2056-2065 ◽  
Author(s):  
Jennifer Carlring ◽  
Marika J. Szabo ◽  
Robert Dickinson ◽  
Evy De Leenheer ◽  
Andrew W. Heath
Keyword(s):  
T Cells ◽  
Immune Responses ◽  
Lipid A ◽  
Keyhole Limpet Hemocyanin ◽  
Potential Candidate ◽  
Antitumor Effects ◽  
Gm Csf ◽  
Humoral Immune ◽  
Monophosphoryl Lipid A

AbstractPersonalized immunotherapy of lymphoma based on tumor idiotype (Id) has shown anti-idiotype humoral immune responses in 40%-50% and cellular immune responses in 50%-75% of follicular lymphoma patients, indicating that this therapy can be clinically successful. We have developed a novel vaccine against lymphoma consisting of an anti-CD40 Ab (ADX40) chemically conjugated to the tumor idiotype A20 and tested it in a murine lymphoma model. BALB/c mice were immunized with 2 doses of immunogen alone or in conjunction with additional adjuvants before tumor challenge. ADX40-Id vaccination resulted in significantly retarded tumor growth and reduced mouse morbidity. Moreover, similar mouse survival was obtained with 2 injections of ADX40-Id as with 8 injections using the standard therapy of keyhole limpet hemocyanin Id + GM-CSF. Co-administration of ADX40-Id with 3-O-deacyl-4′-monophosphoryl lipid A further significantly enhanced vaccine efficacy, resulting in an increased overall survival. Anti-Id–specific Abs were detected at elevated levels after ADX40-Id immunization; however, in vivo depletion of CD4 and/or CD8 T cells before challenge showed that CD8 effector T cells were the major mediators of tumor protection. The results of the present study show that the ADX40-Id conjugate vaccine is a potential candidate as a stand-alone vaccine or in combination with currently licensed adjuvants for lymphoma immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document